[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
We report a case of pleural effusion, pericardial thickening, and pulmonary involvement in a patient with dry cough, dyspnea, edema, and changes in the skin of the lower limbs. Treatment with cabergoline (Sogilen) had been started 4 months earlier. Pleural effusion, pericardial thickening, and impaired pulmonary function (airflow obstruction, increased airway resistance, and reduced carbon monoxide diffusing capacity) were observed. The Naranjo scale pointed to a probable relationship between cabergoline and these adverse effects. We report on outcome after 2 months of follow-up, during which time there was a slow and incomplete improvement in respiratory function. This is the first case in our practice setting of early pleuropulmonary toxicity associated with cabergoline.
Villavicencio
Christian
C
Servicio de Geriatría. Hospital del Mar. Hospital de la Esperanza, Centro Fórum, Instituto de Atención Geriátrica y Sociosanitaria (IAGS) Barcelona. España.
Ramírez-Sarmiento
Alba
A
Gayete
Angel
A
Grau
Santiago
S
Orozco-Levi
Mauricio
M
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D010996:Pleural Effusion / Q000139:chemically induced*; D013997:Time Factors
D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline